CRA recently updated its 2011 review of health technology assessment (HTA) policies, and widened the assessment to cover 16 countries including emerging markets that have recently implemented HTA. Click the link below for a summary of key findings, with a link to the full report.
Pricing implications for drugs included in China’s Rare Diseases Catalogue (RDC)
China’s Rare Disease Catalogue (RDC) plays a growing role in shaping awareness, investment, and access to therapies for rare diseases in China.